XML 55 R17.htm IDEA: XBRL DOCUMENT

Reduction in Workforce	9 Months Ended
Sep. 30, 2019
Reduction in Workforce
Reduction in Workforce	11. Reduction in Workforce In January 2019, the Company announced a reduction in workforce to align with its focus on continued execution of key strategic programs and advancement of selected late-stage research programs toward clinical development. The Company reduced its overall headcount by 51 individuals, with the affected employees primarily focused on early research or the infrastructure in support of VIBATIV, which was sold by the Company to Cumberland Pharmaceuticals Inc. in November 2018. The workforce reduction was substantially completed in the first quarter of 2019, and the Company recorded and paid severance related charges totaling $3.5 million for the nine months ended September 30, 2019, including compensation expense made to affected employees through any minimum statutory notice periods. The severance related charges are presented on the condensed consolidated statements of operations within research and development expenses and selling, general and administrative expenses.

Reduction in Workforce

9 Months Ended

Sep. 30, 2019

11. Reduction in Workforce

In January 2019, the Company announced a reduction in workforce to align with its focus on continued execution of key strategic programs and advancement of selected late-stage research programs toward clinical development. The Company reduced its overall headcount by 51 individuals, with the affected employees primarily focused on early research or the infrastructure in support of VIBATIV, which was sold by the Company to Cumberland Pharmaceuticals Inc. in November 2018.

The workforce reduction was substantially completed in the first quarter of 2019, and the Company recorded and paid severance related charges totaling $3.5 million for the nine months ended September 30, 2019, including compensation expense made to affected employees through any minimum statutory notice periods. The severance related charges are presented on the condensed consolidated statements of operations within research and development expenses and selling, general and administrative expenses.